CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary

CTI BioPharma Corp. announced a poster presentation of its pacritinib program at the 2022 ASCO Annual Meeting taking place from June 3-7, 2022. The presentation will highlight a risk-adjusted safety analysis of pacritinib in patients with myelofibrosis, with details including abstract number 7058 and scheduled for June 4, 2022. Pacritinib is a targeted therapy effective against JAK2 mutations and is FDA-approved for treating myelofibrosis in patients with low platelet counts. CTI's ongoing Phase 3 PACIFICA study further explores pacritinib’s utility in severe thrombocytopenia.

Positive

• Presentation of pacritinib safety analysis at ASCO enhances visibility and credibility.
• FDA-approved pacritinib offers a novel treatment option for myelofibrosis patients.
• Ongoing Phase 3 PACIFICA study may provide additional data supporting pacritinib's effectiveness.

Negative

• None.

SEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021.

The details of the poster presentation are as follows:

Abstract Title: Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF)
Abstract Number: 7058
Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date: Saturday, June 4, 2022
Presentation Time: 8:00 – 11:00 a.m. CDT (11:00 a.m. – 2:00 p.m. ET)
Presenter: Dr. Naveen Pemmaraju

About Pacritinib
Pacritinib is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2^V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Myelofibrosis is often associated with dysregulated JAK2 signaling. Pacritinib has higher inhibitory activity for JAK2 over other family members, JAK3 and TYK2. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^TM is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-at-the-2022-american-society-of-clinical-oncology-annual-meeting-301543545.html

SOURCE CTI BioPharma Corp.

FAQ

What is the focus of the poster presentation by CTI BioPharma at ASCO 2022?

The poster presentation focuses on the risk-adjusted safety analysis of pacritinib for patients with myelofibrosis.

When is CTI BioPharma's presentation scheduled at ASCO 2022?

The presentation is scheduled for June 4, 2022, from 8:00 to 11:00 a.m. CDT.

What is pacritinib used for?

Pacritinib is used for treating adults with myelofibrosis, particularly those with low platelet counts.

What are the key details of the pacritinib program presentation?

The presentation includes the abstract title, 'Risk-adjusted safety analysis of pacritinib', with abstract number 7058.

What ongoing studies is CTI BioPharma conducting related to pacritinib?

CTI BioPharma is conducting the Phase 3 PACIFICA study to assess the efficacy of pacritinib in patients with severe thrombocytopenia.